SYRE (Spyre Therapeutics) E10: $0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SYRE Spyre Therapeutics Inc SYRE
26 GF Score
Price $102.30
! 4 Warning Signs
View Full Analysis

What is Spyre Therapeutics E10?

Spyre Therapeutics SYRE -2.57% 26 E10 is $0.00 as of Jun. 2026. GuruFocus rates SYRE with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

Note: As E10 is a main component used to calculate Shiller PE Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation sectione below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Spyre Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was $-0.425. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.00 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-05), Spyre Therapeutics's current stock price is $102.30. Spyre Therapeutics's E10 for the quarter that ended in Jun. 2026 was $0.00. Spyre Therapeutics's Shiller PE Ratio of today is .


Spyre Therapeutics  (NAS:SYRE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Spyre Therapeutics E10 Related Terms


Spyre Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics E10 Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -49.38 -46.12 -42.60

Spyre Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.20 -43.83 -42.60 -42.11 0.00

SYRE vs CRNX, PTGX, PRAX: E10 Comparison

For the Biotechnology subindustry, Spyre Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spyre Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Shiller PE Ratio falls into.


SYRE
26GF Score
Spyre Therapeutics Inc SYRE
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Spyre Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.425/333.9520*333.9520
=-0.425

Current CPI (Jun. 2026) = 333.9520.

Spyre Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201609 -11.750 241.428 -16.253
201612 -8.250 241.432 -11.412
201703 -11.750 243.801 -16.095
201706 -11.750 244.955 -16.019
201709 -12.000 246.819 -16.236
201712 -9.500 246.524 -12.869
201803 -12.250 249.554 -16.393
201806 -11.500 251.989 -15.241
201809 -13.500 252.439 -17.859
201812 -16.000 251.233 -21.268
201903 -14.750 254.202 -19.377
201906 -13.750 256.143 -17.927
201909 -16.500 256.759 -21.461
201912 -16.250 256.974 -21.118
202003 -14.250 258.115 -18.437
202006 -10.000 257.797 -12.954
202009 -7.250 260.280 -9.302
202012 -8.500 260.474 -10.898
202103 -7.000 264.877 -8.825
202106 -2.500 271.696 -3.073
202109 -7.750 274.310 -9.435
202112 -7.770 278.802 -9.307
202203 -9.250 287.504 -10.744
202206 -6.750 296.311 -7.607
202209 -4.840 296.808 -5.446
202212 -4.690 296.797 -5.277
202303 -4.890 301.836 -5.410
202306 -40.140 305.109 -43.935
202309 -0.860 307.789 -0.933
202312 -1.752 306.746 -1.907
202403 -0.720 312.332 -0.770
202406 -0.847 314.175 -0.900
202409 -1.347 315.301 -1.427
202412 -0.810 315.605 -0.857
202503 -0.600 319.799 -0.627
202506 -0.605 322.561 -0.626
202509 -0.184 324.800 -0.189
202512 -0.700 324.054 -0.721
202603 -0.740 330.213 -0.748
202606 -0.425 333.952 -0.425

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $0.00 mean?
Spyre Therapeutics (SYRE) has a E10 of $0.00 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Spyre Therapeutics and its competitors.
Is Spyre Therapeutics' E10 too high?
Spyre Therapeutics' current E10 is $0.00. Overall, Spyre Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' E10 compare to CRNX and PTGX?
Spyre Therapeutics' E10 of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Spyre Therapeutics and its competitors. Spyre Therapeutics's current E10 is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (SYRE) has a current E10 of $0.00. The current E10 is $0.00. Spyre Therapeutics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Spyre Therapeutics (SYRE), the current E10 is $0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spyre Therapeutics Business Description

Other Exchanges 3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
26GF Score

Get the complete analysis for SYRE

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$102.30
Price